Epigenetic silencing of HTATIP2 in glioblastoma enhances nuclear translocation of the DNA-repair protein MPG affecting treatment resistance
Détails
Télécharger: Nguyen_HTATIP2_b508c5e1-0111-4d21-ac33-6ee2a036393e.pdf (2868.88 [Ko])
Etat: Public
Version: de l'auteur⸱e
Licence: CC BY 4.0
Etat: Public
Version: de l'auteur⸱e
Licence: CC BY 4.0
ID Serval
serval:BIB_61686B583679
Type
Autre: (aucun autre type ne convient)
Collection
Publications
Institution
Titre
Epigenetic silencing of HTATIP2 in glioblastoma enhances nuclear translocation of the DNA-repair protein MPG affecting treatment resistance
Date de publication
15/11/2022
Langue
anglais
Résumé
DNA methylome analysis of glioblastoma (GBM) identified the HIV-1 Tat interactive
protein 2 (HTATIP2) gene as aberrantly methylated and silenced. HTATIP2 is a negative
regulator of importin β-mediated (KPNB1) cytoplasmic-nuclear translocation of proteins and its
deregulation may alter the functionality of cancer relevant nuclear proteins. We propose NMethylpurine-
DNA Glycosylase (MPG), responsible for removing alkylated bases and initiating
base excision repair (BER), as a potential GBM relevant candidate. Here we investigated the
role of epigenetic silencing of HTATIP2 on the subcellular localization of MPG, and MPGmediated
DNA repair.
Induction of HTATIP2 expression in GBM cells lead to a significant shift of
predominantly nuclear to cytoplasmic MPG, while depletion of endogenous levels of HTATIP2
resulted in enhanced nuclear MPG localization. We observed exclusion of MPG from the area
exhibiting co-localization of HTATIP2 and KPNB1 in proximity to the nuclear membrane,
suggesting competition of HTATIP2 with MPG to bind to KPNB1. In accordance,
pharmacologic inhibition of KPNB1 similarly induced cytoplasmic retention of MPG as
HTATIP2 expression. Reduced nuclear MPG localization, induced by HTATIP2 expression or
depletion of MPG, yielded less P-H2AX-positive cells upon treatment with an alkylating agent.
This suggested reduced MPG-mediated formation of apurinic/apyrimidinic (AP) sites, leaving
behind unrepaired DNA lesions, hence, reflecting a reduced capacity of BER in response to
the alkylating agent.
Taken together, these results suggest that epigenetic silencing of HTATIP2 may
increase nuclear localization of MPG, thereby increasing the capacity of the tumor cells to
repair treatment related lesions and eventually contributing to treatment resistance.
protein 2 (HTATIP2) gene as aberrantly methylated and silenced. HTATIP2 is a negative
regulator of importin β-mediated (KPNB1) cytoplasmic-nuclear translocation of proteins and its
deregulation may alter the functionality of cancer relevant nuclear proteins. We propose NMethylpurine-
DNA Glycosylase (MPG), responsible for removing alkylated bases and initiating
base excision repair (BER), as a potential GBM relevant candidate. Here we investigated the
role of epigenetic silencing of HTATIP2 on the subcellular localization of MPG, and MPGmediated
DNA repair.
Induction of HTATIP2 expression in GBM cells lead to a significant shift of
predominantly nuclear to cytoplasmic MPG, while depletion of endogenous levels of HTATIP2
resulted in enhanced nuclear MPG localization. We observed exclusion of MPG from the area
exhibiting co-localization of HTATIP2 and KPNB1 in proximity to the nuclear membrane,
suggesting competition of HTATIP2 with MPG to bind to KPNB1. In accordance,
pharmacologic inhibition of KPNB1 similarly induced cytoplasmic retention of MPG as
HTATIP2 expression. Reduced nuclear MPG localization, induced by HTATIP2 expression or
depletion of MPG, yielded less P-H2AX-positive cells upon treatment with an alkylating agent.
This suggested reduced MPG-mediated formation of apurinic/apyrimidinic (AP) sites, leaving
behind unrepaired DNA lesions, hence, reflecting a reduced capacity of BER in response to
the alkylating agent.
Taken together, these results suggest that epigenetic silencing of HTATIP2 may
increase nuclear localization of MPG, thereby increasing the capacity of the tumor cells to
repair treatment related lesions and eventually contributing to treatment resistance.
Open Access
Oui
Financement(s)
Fonds national suisse / Projets / 31003A_182821
Autre / KFS-4461-02-2018
Création de la notice
15/11/2022 19:15
Dernière modification de la notice
09/05/2024 6:27